Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bph.15194 http://scihub22266oqcxt.onion/10.1111/bph.15194 32639031!7361899!32639031     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Pharmacol 2020 ; 177 (21): 4971-4974 Nephropedia Template TP {{tp|p=32639031|t=2020. Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19?|pdf=|usr=}}{{32639031}} gab.com Text Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19 JO: Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32639031 #FOAvip In the search to rapidly identify effective therapies that will mitigate the morbidity and mortality of COVID-19, attention has been directed towards the repurposing of existing drugs. Candidates for repurposing include drugs that target COVID-19 pathobiology, including agents that alter angiotensin signalling. Recent data indicate that key findings in COVID-19 patients include thrombosis and endotheliitis. Activation of proteinase-activated receptor 1 (PAR1), in particular by the serine protease thrombin, is a critical element in platelet aggregation and coagulation. PAR1 activation also impacts on the actions of other cell types involved in COVID-19 pathobiology, including endothelial cells, fibroblasts and pulmonary alveolar epithelial cells. Vorapaxar is an approved inhibitor of PAR1, used for treatment of patients with myocardial infarction or peripheral arterial disease. We discuss evidence for a possible beneficial role for vorapaxar in the treatment of COVID-19 patients and other as-yet non-approved antagonists of PAR1 and proteinase-activated receptor 4 (PAR4). LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. Twit Text FOAVip Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19 ????Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=32639031 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32639031 #FOAvip English Wikipedia <ref>{{Cite pmid|32639031}}</ref> Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19? #MMPMID32639031 Sriram K; Insel PA Br J Pharmacol 2020[Nov]; 177 (21): 4971-4974 PMID32639031show ga In the search to rapidly identify effective therapies that will mitigate the morbidity and mortality of COVID-19, attention has been directed towards the repurposing of existing drugs. Candidates for repurposing include drugs that target COVID-19 pathobiology, including agents that alter angiotensin signalling. Recent data indicate that key findings in COVID-19 patients include thrombosis and endotheliitis. Activation of proteinase-activated receptor 1 (PAR1), in particular by the serine protease thrombin, is a critical element in platelet aggregation and coagulation. PAR1 activation also impacts on the actions of other cell types involved in COVID-19 pathobiology, including endothelial cells, fibroblasts and pulmonary alveolar epithelial cells. Vorapaxar is an approved inhibitor of PAR1, used for treatment of patients with myocardial infarction or peripheral arterial disease. We discuss evidence for a possible beneficial role for vorapaxar in the treatment of COVID-19 patients and other as-yet non-approved antagonists of PAR1 and proteinase-activated receptor 4 (PAR4). LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. |Animals[MESH] |Betacoronavirus/isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Lactones/*administration & dosage/pharmacology[MESH] |Pandemics[MESH] |Platelet Aggregation Inhibitors/administration & dosage/pharmacology[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH] |Pyridines/*administration & dosage/pharmacology[MESH] |Receptor, PAR-1/*antagonists & inhibitors/metabolism[MESH] |Receptors, Thrombin/antagonists & inhibitors/metabolism[MESH]Proteinase-activated receptor 1: A target for repurposing in the treat(epmc).pdf DeepDyve Pubget Overpricing